EHA 2026 | Updated results: Phase II study evaluating elritercept in patients with transfusion-dependent LR-MDS

In this EHA meeting, we have analyzed the updated results of 96 patients included in the clinical trial. This clinical trial incorporates patients with lower risk transfusion MDS patients and transfusion dependency. And in this trial, we identify that the responses are around overall 56%, overall response rate, and response increase when the patient has endogenous erythropoietin levels below 500. And also, the responses are present in patients with high transfusion burden and non-ringed sideroblast phenotype that are patients difficult to treat with other available drugs nowadays, like ESAs or Luspatercept. Regarding transfusion independencies, that is the major goal of this trial regarding efficacy, we achieved up to 38% of transfusion independencies in the overall population, and this increase when the patient has lower endogenous EPO levels. And also, it did not decrease a lot with patients in the high transfusion burden and in the non-ringed sideroblast phenotype. So it’s important for treating these patients that are not responding well to other available drugs. Also, we confirm safety and tolerability of this novel compound with no relevant adverse events and all the adverse events present are in grades one and two and also we have also identified several responses in other cytopenias present in the patients like neutropenia or thrombocytopenia. So in an overview we can confirm that this novel drug is very well tolerated, it’s safe and induces responses in a difficult to treat population within a high transfusion burden and non-ringed sideroblast patient and this drug induces a prolonged and rapid transfusion independency for these patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.